MarketMoodz
Goldman backs Biohaven as under-the-radar biotech with IgAN degrader potential
Goldman Sachs has initiated coverage on Biohaven (BHVN) with a Buy rating and a $23 12-month target, spotlighting BHV-1400 as a potentially best-in-class IgA nephropathy degrader. The note also flags a separate epilepsy asset and a broader late-stage pipeline, suggesting a multi-catalyst upside for a stock that’s been out of favor.
Key Takeaways
- Goldman Sachs initiated Biohaven with a Buy rating and a 12-month target of $23.
- BHVN-1400 could be a best-in-class IgA nephropathy degrader central to the thesis.
- OPAKALIM (Kv7 activator) for focal onset epilepsy has a pivotal readout expected in 2H26.
- Goldman sees a large U.S. IgAN addressable market (> $40B) and a broad late-stage pipeline beyond IgAN.
People Involved
- Corinne JohnsonGoldman Sachs analyst
Entities Involved
- Biohaven Pharmaceutical, Inc. (BHVN)Biotech company developing BHV-1400 and OPAKALIM
- Goldman SachsInvestment bank initiating coverage on Biohaven
MarketMoodz Analysis
For investors, the note lays out a near-term catalyst-driven thesis: pivotal trials for BHV-1400 are slated to begin in early 2026, and OPAKALIM’s pivotal readout is expected in 2H26, providing multiple data points to re-rate the stock. The IgAN opportunity—cited by Goldman as a U.S. market north of $40 billion—adds a clear, sizable addressable market to the thesis.
Historically, biotech initiations can unlock re-ratings when catalysts materialize, especially for clinical-stage names trading well below peak hype. Biohaven’s stock has fallen meaningfully over the past year, creating upside if the 2026 catalysts land as expected and if BHV-1400 demonstrates competitive efficacy without immunosuppression concerns, as analyst Corinne Johnson suggested.
What to watch next: updates on the BHV-1400 pivotal trial start in early 2026, OPAKALIM’s 2H26 readout, potential partnerships or licensing deals tied to IgAN assets, and any early signals from Phase 2/3 data that could shift risk-reward.
Source: Original Article